Autologous Transplantation
6
1
1
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
6 treatments under study, led by Plerixafor
Research Leaders
5 sponsors active, led by Genzyme, a Sanofi Company
Related Conditions
Often studied with 8 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 6 trials
100.0%
+13.4% vs benchmark
17%
1 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (6)
Fertility Restoration With Autografting of Cryopreserved Immature Testicular Tissue
Emdogain Adjunctive to Autotransplantation
Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662).
Long-Term Follow-up Study for Non-Hodgkin's Lymphoma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3101 Study (NCT00103610).
Alteration in Timing of Plerixafor Administration
Comparison of Autologous Mesenchymal Stem Cells and Mononuclear Cells on Diabetic Critical Limb Ischemia and Foot Ulcer
Research Network
Common Treatments
- Plerixafor3
- Granulocyte Colonystimulating Factor2
- Autologous Transplantation Of Cryopreserved Testicular Tissue1
- Emdogain Emd Test1
- Sham Group1
Active Sponsors
- Genzyme, a Sanofi Company3
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain1
- Third Military Medical University1
- Emory University1
- Universidad Complutense de Madrid1
Top Investigators
Emory University Winship Cancer Institute
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Endocrinology and Metabolism Department, the south west Hospital of the Third Military Medical University
Related Conditions
- Infertility1
- Autotransplantation1
- Multiple Myeloma1
- Nonhodgkins Lymphoma1
- Enamel Matrix Derivatives1